1YG0.F Mendus AB (publ)
- Market cap
- EUR 27.4M
- P/E
- -
- P/B
- 0.66x
- ROE
- -15.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1YG0.F undervalued?
Graham numberThe Graham number of Mendus AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mendus AB (publ) fundamental analysis
No fundamental analysis for Mendus AB (publ) yet.
Mendus AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to s…
Full company profileMendus AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mendus AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -129M | -135M | -101M | -131M | -112M | -81.2M |
| EBITDA | - | -129M | -92.2M | -121M | -104M | -74.2M |
| Net Income | -133M | -139M | -102M | -128M | -113M | -84.8M |
| EPS | -12 | -13 | -2.35 | -2.55 | -1.85 | -1.34 |
| Balance Sheet | ||||||
| Total Assets | 721M | 620M | 756M | 696M | 628M | 622M |
| Total Liabilities | 64.2M | 106M | 51.2M | 51.2M | 43.3M | 76.4M |
| Shareholders' Equity | 657M | 514M | 705M | 645M | 585M | 545M |
| Cash & Short-term Investments | 155M | 41.9M | 121M | 102M | 64.7M | 59.9M |
| Cash Flow | ||||||
| Operating Cash Flow | -138M | -109M | -163M | -79.7M | -81.5M | -66.6M |
| Capital Expenditure | 1.36M | 12.3M | 1.82M | 1.84M | 307K | 802K |
| Free Cash Flow | -139M | -122M | -165M | -81.5M | -81.8M | -67.4M |
| Ratios | ||||||
| ROE | -20.3% | -27.0% | -14.4% | -19.9% | -19.4% | -15.6% |
| ROA | -18.5% | -22.4% | -13.4% | -18.4% | -18.0% | -13.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Mendus AB (publ) dividends
Mendus AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Jun 3, 2024.
Who owns Mendus AB (publ)
- Insiders 62.84%
- Institutions 16.06%
- Public & others 21.10%
- Shares outstanding 63.5M
- Free float 23.8M
Mendus AB (publ) company profile
- Company name
- Mendus AB (publ)
- Ticker
- 1YG0.F
- ISIN
- SE0022239950
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- Västra Trädgårdsgatan 15, Stockholm, Sweden, 111 53
- Phone
- 46 87 32 84 00
- Website
- mendus.com
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Mendus AB (publ) management
4- Dr. Hans Preusting Ph.D.Chief Operating Officer · born 1962
- Dr. Erik Manting Ph.D.Chief Executive Officer · born 1971
- Ms. Lotta FermChief Financial Officer · born 1966
- Dr. Tariq Mughal M.D.Chief Medical & Scientific Officer